Detected ·
Anaheim Bio
€40MSeries A
Anaheim Bio has launched with a €40 million Series A to advance its lead molecule ANA1 into clinical trials for calcium pyrophosphate deposition disease (CPPD).
- Website
- —
- —
- Amount
- €40 000 000 EUR
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-05 20:08:34 UTC
- Signal ID
- eed41273-02ab-4b82-8ea3-f43dbf5cd9da
As the API returns it
{
"id": "eed41273-02ab-4b82-8ea3-f43dbf5cd9da",
"created_at": "2026-11-05T20:08:34.751495Z",
"company_name": "Anaheim Bio",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 40000000,
"funding_currency": "EUR",
"funding_stage": "series_a",
"message": "*Anaheim Bio has launched with a €40 million Series A to advance its lead molecule ANA1 into clinical trials for calcium pyrophosphate deposition disease (CPPD).*"
}